Kaya operates a network of specialized dermatology clinics providing skin, hair, and body treatments alongside a range of dermatologist-formulated retail skincare products.
The company claims a moat based on dermatological expertise and brand trust, but persistent net losses and negative margins across multiple years suggest a lack of durable pricing power or cost advantages. While NPS scores are high, the inability to translate customer satisfaction into positive ROIC indicates the brand does not currently function as a wide economic moat.
Capital has been primarily directed toward clinic renovations and technology upgrades (Klear AI) to stem revenue declines. The recent divestment of the Middle East business was a significant move to consolidate operations and improve the balance sheet, though historical reinvestment has failed to generate positive returns for shareholders.
Five years out, the business collapsed because the 'brand refresh' and AI investments failed to arrest the structural decline in revenue. The company remained a 'charity' for its employees and suppliers, consuming promoter capital without ever reaching a self-sustaining bottom line. As the Middle East divestment proceeds were exhausted on operating losses rather than growth, the promoter's willingness to provide interest-free loans finally evaporated, leading to a liquidity crunch and a total wipeout of equity value as the negative net worth became insurmountable.
RichFakir rates Kaya Ltd's business quality as poor — 7/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Kaya Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →